Cellumen and Mitsubishi Tanabe Pharma Corporation Collaborate in Discovery Toxicology
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Cellumen, Inc. has announced an agreement with Mitsubishi Tanabe Pharma Corporation (MTPC) to develop panels of biomarkers that identify toxicity early in the drug development process.
“We’re pleased to announce this collaboration with MTPC,” says D. Lansing Taylor, PhD, CEO of Cellumen. “By working together to develop biomarker panels, we hope to identify toxic liabilities much earlier in the drug development process than currently exists in the marketplace. Our ultimate goal is to enable MTPC to prioritize its lead drug series.”
